<DOC>
	<DOCNO>NCT01711814</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety efficacy ASP015K subject Rheumatoid Arthritis ( RA ) complete precede Phase 2 ASP015K RA study .</brief_summary>
	<brief_title>A Study Evaluate Long-term Safety Efficacy ASP015K Subjects Previously Enrolled Phase 2 ASP015K Rheumatoid Arthritis Study</brief_title>
	<detailed_description>This study comprise 104 week treatment period begin Day 1 study drug administration 30-day follow-up period permanent termination clinical development product , whichever early .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Subject complete week 12 visit one Phase 2 , ASP015K Rheumatoid Arthritis study within previous 14 day . Male Female subject must willing comply contraception requirement well restriction regard egg sperm donation Subject condition consider Principal Investigator Medical Monitor preclude adequate evaluation drug safety Subject schedule receive investigational drug ASP015K course study Subject schedule receive prohibit medication Subject plan major surgery Subject discontinue study drug due meeting study drug discontinuation criterion prior completion Week 12 visit precede study fulfills study drug discontinuation criterion final study visit precede study Subject range laboratory value within 14 day Day 1 study dose Absolute lymphocyte count ( ALC ) &lt; 500/mm3 Creatine Phosphokinase ( CPK ) &gt; 1.5 x upper limit normal unless level stable least 2 consecutive blood draw ( least 7 day apart ) , subject symptom muscle ache , weakness , severe unusual muscle cramp</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>ASP015K</keyword>
</DOC>